-+ 0.00%
-+ 0.00%
-+ 0.00%

ALDEYRA THERAPEUTICS - EXPECTS CLINICAL PROGRAM FOR ADX-2191 IN PVRL WILL NEED REDESIGN - SEC FILING

Reuters·11/09/2026 21:29:03